-
61.发明公开公开(公告)号：US20230346641A1
公开(公告)日：2023-11-02
申请号：US18041635
申请日：2021-08-20
发明人： Daniel KULLMANN , Carmen LEMA MARTINEZ , Gregoire SCHWACH , Joerg LUEMKEMANN , Thomas ZUMSTEIN , Pascal Markus HOFER , Jonas LUZIO
CPC分类号： A61J1/1468 , F26B5/06 , A61K9/19
摘要： A lyophilisate retainer for lyophilizing a substrate is disclosed that includes a three dimensional scaffold body having pores. The pores of the scaffold body are configured to receive and hold the substrate. The scaffold body is made of a scaffold material providing heat transfer properties in lyophilisation to induce heat transfer to the substrate held in the pores of the scaffold body.
-
公开(公告)号：US20230340134A1
公开(公告)日：2023-10-26
申请号：US18335789
申请日：2023-06-15
CPC分类号： C07K16/2866 , A61K39/39591 , A61K47/183 , A61K47/26 , C07K1/14 , A61K39/3955 , A61K47/20 , A61K9/0019
摘要： The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.
-
公开(公告)号：US20230331796A1
公开(公告)日：2023-10-19
申请号：US17850922
申请日：2022-06-27
CPC分类号： C07K14/472 , B01D15/3809 , C07K1/22 , C07K16/18 , C07K2317/92 , C07K2317/94 , C07K2319/00
摘要： Herein is reported a fusion polypeptide according to formula I (TAG-X1-C1qA-X2-C1qB-X3-C1qC-X4), comprising a fragment of SEQ ID NO: 01 (C1qA), a fragment of SEQ ID NO: 03 (C1qB), a fragment of SEQ ID NO: 05 (C1qC) and optionally a tag (TAG).
-
![SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION](/abs-image/US/2023/10/19/US20230331715A1/abs.jpg.150x150.jpg)
64.发明公开公开(公告)号：US20230331715A1
公开(公告)日：2023-10-19
申请号：US18319860
申请日：2023-05-18
发明人： Xianfeng LIN , Jianping WANG , Hongying YUN , Xiufang ZHENG
IPC分类号： C07D417/12 , C07D277/64 , C07D513/04 , C07F9/6541 , A61P31/20
CPC分类号： C07D417/12 , A61P31/20 , C07D277/64 , C07D513/04 , C07F9/6541
摘要： The present invention provides novel compounds having the general formula:
wherein R1 to R3 are as described herein, compositions including the compounds and methods of using the compounds.-
公开(公告)号：US11788205B2
公开(公告)日：2023-10-17
申请号：US16906931
申请日：2020-06-19
发明人： Christian Klein , Ekkehard Moessner , Lydia Jasmin Hanisch , Wei Xu , Camille Loise Sophie Delon , Diana Darowski , Christian Jost , Vesna Pulko
CPC分类号： C40B30/06 , C07K16/2809 , C12N15/1037 , C12N15/1086 , C12N15/86 , G01N33/505 , G01N33/57492 , C07K2317/31 , C12N2740/15043
摘要： The present invention generally relates to specificity assays using cell cultures, in particular to chimeric antigen receptor (CAR) expressing reporter T (CAR-T cell) assays to test antigen binding moieties in different formats. Furthermore, the present invention relates to the use of CAR-T cells, transfected/transduced with an engineered chimeric antigen receptor (CAR) comprising a target antigen binding moiety capable of specific binding to a target antigen, e.g., tumor associated antigens.
-
公开(公告)号：US11787873B2
公开(公告)日：2023-10-17
申请号：US16744697
申请日：2020-01-16
发明人： Rebecca Croasdale-Wood , Lydia Jasmin Hanisch , Guy Georges , Thomas Hofer , Ralf Hosse , Christian Klein , Ekkehard Moessner , Samuel Moser , Wolfgang Schaefer , Juergen Michael Schanzer , Werner Scheuer , Claudio Sustmann , Pablo Umana
IPC分类号： C07K16/32 , A61K31/713 , C12N5/10 , C12N15/63 , A61K39/00
CPC分类号： C07K16/32 , A61K31/713 , C12N5/10 , C12N15/63 , A61K2039/505 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/522 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/64 , C07K2317/66 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/92 , C07K2317/94
摘要： The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
-
公开(公告)号：US11787868B2
公开(公告)日：2023-10-17
申请号：US17130477
申请日：2020-12-22
发明人： Harald Duerr , Sebastian Fenn , Ulrich Goepfert , Sabine Imhof-Jung , Christian Klein , Laurent Lariviere , Michael Molhoj , Joerg Thomas Regula , Petra Rueger , Wolfgang Schaefer
CPC分类号： C07K16/2881 , A61P25/28 , C07K16/18 , C07K16/468 , A61K2039/505 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/522 , C07K2317/55 , C07K2317/56 , C07K2317/64
摘要： Herein are provided bispecific anti-human A-betalhuman transferrin receptor antibodies and methods of using the same.
-
公开(公告)号：US20230322950A1
公开(公告)日：2023-10-12
申请号：US18162508
申请日：2023-01-31
IPC分类号： C07K16/42 , C07K14/705 , C07K14/725 , A61K39/00
CPC分类号： C07K16/42 , C07K14/70521 , C07K14/70578 , C07K14/7051 , A61K39/4611 , A61K39/4633 , A61K39/4643 , C07K2319/03 , C07K2317/565 , C07K2319/02 , C07K2317/52 , C07K2317/24 , A61K38/00
摘要： The present invention generally relates to antigen binding receptors capable of specific binding to an Fc domain comprising the amino acid mutation P329G according to EU numbering. The present invention also relates to T cells, transduced with a antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies. Furthermore, the invention relates to a kit comprising the transduced T cells of the invention and/or nucleic acid molecules, vectors encoding the antigen binding receptors of the present invention and tumor targeting antibodies comprising a mutated Fc domain.
-
公开(公告)号：US20230317204A1
公开(公告)日：2023-10-05
申请号：US17922342
申请日：2021-04-29
摘要： The present invention provides a method comprising (a) obtaining a single cell gene expression profile comprising gene expression measurements for a set of genes, for a plurality of cells, and a single cell protein expression profile comprising protein expression measurements for two or more proteins, for the plurality of cells; (b) using the single cell protein expression profiles and an unsupervised learning method to assign a cell type class to at least some of the plurality of cells; and(d) applying a feature selection process to the single gene expression profiles to identify genes in the single cell gene expression profiles that are predictive of the cell type classes assigned in step (b), wherein the genes identified in step (d) form a predictor set of genes for predicting the cell type of one or more cells.
-
公开(公告)号：US20230312710A1
公开(公告)日：2023-10-05
申请号：US18052526
申请日：2022-11-03
发明人： Thomas Hofer , Claudia Ferrara Koller , Ekkehard Moessner , Mi He
CPC分类号： C07K16/2803 , A61P35/00 , C07K16/3061 , C07K2317/92 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565
摘要： The present invention relates to antibodies against human CD19 (anti-human CD19 antibodies), methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
-
-
-
-
-
-
-
-
-
搜索结果
5922 条记录 (耗时 0.041 秒)
